



GP  
1641

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Attorney Docket No.: 023070-121000US  
Client Ref. No.: 2001-512

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

#3

On April 12, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: [Signature]

RECEIVED

APR 22 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GERSHWIN *et al.*

Application No.: 10/052,788

Filed: November 8, 2001

For: EPSILON IMMUNOGLOBULIN  
CHAIN DERIVED PEPTIDES FOR  
INDUCTION OF ANTI-IGE  
ANTIBODIES

Examiner: Not yet assigned

Art Unit: 1641

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office  
Box SEQUENCE  
P.O. Box 2327  
Arlington, VA 22202

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Nonprovisional Application mailed February 19, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.